PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22348531-6	2012	Transfection with an ERK-, IkappaB-, or c/EBPbeta-specific siRNA or pretreatment with an ERK-, p38 MAPK-, or p300-selective inhibitor considerably abrogated the melatonin-mediated inhibition of proinflammatory mediators.	Melatonin	161-170	mitogen-activated protein kinase 1	Homo sapiens	21-24	
22348531-6	2012	Transfection with an ERK-, IkappaB-, or c/EBPbeta-specific siRNA or pretreatment with an ERK-, p38 MAPK-, or p300-selective inhibitor considerably abrogated the melatonin-mediated inhibition of proinflammatory mediators.	Melatonin	161-170	mitogen-activated protein kinase 1	Homo sapiens	89-92	
22348531-8	2012	Collectively, these results indicate that melatonin suppresses proinflammatory mediators by simultaneously targeting the multiple signaling such as ERK/p38 MAPK, c/EBPbeta, NF-kappaB, and p300, in LPS-stimulated VSM cell line CRL1999, and suggest that melatonin is a potential candidate compound for the treatment of proinflammatory disorders.	Melatonin	42-51	mitogen-activated protein kinase 1	Homo sapiens	148-151	
22348531-8	2012	Collectively, these results indicate that melatonin suppresses proinflammatory mediators by simultaneously targeting the multiple signaling such as ERK/p38 MAPK, c/EBPbeta, NF-kappaB, and p300, in LPS-stimulated VSM cell line CRL1999, and suggest that melatonin is a potential candidate compound for the treatment of proinflammatory disorders.	Melatonin	252-261	mitogen-activated protein kinase 1	Homo sapiens	148-151